Literature DB >> 24966974

Hydroxysafflor yellow A attenuates ischemia/reperfusion-induced liver injury by suppressing macrophage activation.

Shujun Jiang1, Zhen Shi1, Changyong Li2, Chunlei Ma1, Xianyong Bai1, Chaoyun Wang3.   

Abstract

Hydroxysafflor yellow A (HSYA), a major constituent in the hydrophilic fraction of the safflower plant, can retard the progress of hepatic fibrosis. However, the anti-inflammatory properties and the underlying mechanisms of HSYA on I/R-induced acute liver injury are unknown. Inhibiting macrophage activation is a potential strategy to treat liver ischemia/reperfusion (I/R) injury. In this study, we investigated the therapeutic effect of HSYA on liver I/R injury and the direct effect of HSYA on macrophage activation following inflammatory conditions. The therapeutic effects of HSYA on I/R injury were tested in vivo using a mouse model of segmental (70%) hepatic ischemia. The mechanisms of HSYA were examined in vitro by evaluating migration and the cytokine expression profile of the macrophage cell line RAW264.7 exposed to acute hypoxia and reoxygenation (H/R). Results showed that mice pretreated with HSYA had reduced serum transaminase levels, attenuated inflammation and necrosis, reduced expression of inflammatory cytokines, and less macrophage recruitment following segmental hepatic ischemia. In vitro HSYA pretreated RAW264.7 macrophages displayed reduced migratory response and produced less inflammatory cytokines. In addition, HSYA pretreatment down-regulated the expression of matrix matalloproteinase-9 and reactive oxygen species, and inhibited NF-κB activation and P38 phosphorylation in RAW264.7 cells. Thus, these data suggest that HSYA can reduce I/R-induced acute liver injury by directly attenuating macrophage activation under inflammatory conditions.

Entities:  

Keywords:  Hydroxysafflor yellow A; cell migration; inflammatory cytokines; liver ischemia/reperfusion injury; macrophage; reactive oxygen species

Mesh:

Substances:

Year:  2014        PMID: 24966974      PMCID: PMC4069906     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  39 in total

Review 1.  Nuclear factor-kappaB in the liver: friend or foe?

Authors:  Robert F Schwabe; David A Brenner
Journal:  Gastroenterology       Date:  2007-06       Impact factor: 22.682

2.  Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection.

Authors:  J Belghiti; K Hiramatsu; S Benoist; P Massault; A Sauvanet; O Farges
Journal:  J Am Coll Surg       Date:  2000-07       Impact factor: 6.113

Review 3.  Role of Kupffer cells in host defense and liver disease.

Authors:  Manfred Bilzer; Frigga Roggel; Alexander L Gerbes
Journal:  Liver Int       Date:  2006-12       Impact factor: 5.828

4.  Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1.

Authors:  H Nakano; M Shindo; S Sakon; S Nishinaka; M Mihara; H Yagita; K Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

Review 5.  Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury.

Authors:  Hartmut Jaeschke; John J Lemasters
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

Review 6.  Mechanisms of Liver Injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways.

Authors:  Robert F Schwabe; David A Brenner
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-04       Impact factor: 4.052

7.  Metalloproteinase-9 deficiency protects against hepatic ischemia/reperfusion injury.

Authors:  Takashi Hamada; Constantino Fondevila; Ronald W Busuttil; Ana J Coito
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

8.  Evidence that hydroxysafflor yellow A protects the heart against ischaemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening.

Authors:  Yi-Na Liu; Zhong-Min Zhou; Peng Chen
Journal:  Clin Exp Pharmacol Physiol       Date:  2007-10-17       Impact factor: 2.557

9.  Mitogen-activated protein kinases: specificity of response to dose of ionizing radiation in liver.

Authors:  H Narang; M Krishna
Journal:  J Radiat Res       Date:  2004-06       Impact factor: 2.724

10.  Protective effects of hydroxysafflor yellow A on acute and chronic congestive cardiac failure mediated by reducing ET-1, NOS and oxidative stress in rats.

Authors:  Haibo He; Xianzhe Yang; Mengqiong Shi; Xiaowei Zeng; Jun Yang; Limao Wu; Lianda Li
Journal:  J Pharm Pharmacol       Date:  2008-01       Impact factor: 3.765

View more
  14 in total

1.  Inhibition of 15-lipoxygenase (15-LOX) reverses hypoxia-induced down-regulation of potassium channels Kv1.5 and Kv2.1Inhibition of 15-lipoxygenase (15-LOX) reverses hypoxia-induced down-regulation of potassium channels Kv1.5 and Kv2.1.

Authors:  Wenjuan Liu; Di Wang; Kaibin Song; Li Chen; Yanmei Zhu; Peifang Liu; Yulan Zhu
Journal:  Int J Clin Exp Med       Date:  2014-11-15

2.  Chinese Herbal Preparation Xuebijing Potently Inhibits Inflammasome Activation in Hepatocytes and Ameliorates Mouse Liver Ischemia-Reperfusion Injury.

Authors:  Xiqiang Liu; Zhiqiu Hu; Bin Zhou; Xiang Li; Ran Tao
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

3.  Hydroxysafflor Yellow A Inhibits LPS-Induced NLRP3 Inflammasome Activation via Binding to Xanthine Oxidase in Mouse RAW264.7 Macrophages.

Authors:  Xiaolong Xu; Yuhong Guo; Jingxia Zhao; Ning Wang; Junying Ding; Qingquan Liu
Journal:  Mediators Inflamm       Date:  2016-06-28       Impact factor: 4.711

Review 4.  Natural Medicines Used in the Traditional Tibetan Medical System for the Treatment of Liver Diseases.

Authors:  Qi Li; Hai-Jiao Li; Tong Xu; Huan Du; Chen-Lei Huan Gang; Gang Fan; Yi Zhang
Journal:  Front Pharmacol       Date:  2018-01-30       Impact factor: 5.810

5.  Hydroxysafflor Yellow A Attenuates the Apoptosis of Peripheral Blood CD4+ T Lymphocytes in a Murine Model of Sepsis.

Authors:  Jinping Wang; Ping Wang; Shuiqing Gui; Yun Li; Runhua Chen; Renqing Zeng; Peiyan Zhao; Hanwei Wu; Zheyu Huang; Jianlong Wu
Journal:  Front Pharmacol       Date:  2017-09-06       Impact factor: 5.810

6.  Effects of Taohongsiwu decoction on the expression of α-SMA and TGF-β1 mRNA in the liver tissues of a rat model of hepatic cirrhosis.

Authors:  Tongsheng Wang; Deling Wu; Peipei Li; Ke Zhang; Shanjun Tao; Zhu Li; Jun Li
Journal:  Exp Ther Med       Date:  2017-06-16       Impact factor: 2.447

7.  Neuroprotection of hydroxysafflor yellow A in experimental cerebral ischemia/reperfusion injury via metabolic inhibition of phenylalanine and mitochondrial biogenesis.

Authors:  Suning Chen; Mao Sun; Xianghui Zhao; Zhifu Yang; Wenxing Liu; Jinyi Cao; Yi Qiao; Xiaoxing Luo; Aidong Wen
Journal:  Mol Med Rep       Date:  2019-02-15       Impact factor: 2.952

8.  Effects of HSYA on the proliferation and apoptosis of MSCs exposed to hypoxic and serum deprivation conditions.

Authors:  Xiaoqing Song; Lining Su; Haifeng Yin; Jin Dai; Huiping Wei
Journal:  Exp Ther Med       Date:  2018-05-03       Impact factor: 2.447

Review 9.  Hydroxysafflor Yellow A: A Promising Therapeutic Agent for a Broad Spectrum of Diseases.

Authors:  Hui Ao; Wuwen Feng; Cheng Peng
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-25       Impact factor: 2.629

10.  Three Ingredients of Safflower Alleviate Acute Lung Injury and Inhibit NET Release Induced by Lipopolysaccharide.

Authors:  Yun-Peng Wang; Yu Guo; Ping-Shan Wen; Zhen-Zhen Zhao; Jian Xie; Kai Yang; Qing Yang; Jia-Feng Wang; Xiao-Ming Deng
Journal:  Mediators Inflamm       Date:  2020-02-29       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.